Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

PTHS - Pelthos Therapeutics Inc. Последние... | Finranks

Home

/

PTHS

P

Pelthos Therapeutics Inc. (PTHS)

ASE – Цена в реальном времени. Валюта: USD

29.03

-0.18 (-0.62%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference

Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference

DURHAM, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, (“Pelthos”), today announced that CEO Scott Plesha will present at 11:05 am ET and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference on June 4, 2026 in New York. Investors interested in arranging one-on-one meetings should contact their Jefferies representative.

Pelthos Therapeutics Q1 Earnings Call Highlights

Pelthos Therapeutics Q1 Earnings Call Highlights

Pelthos Therapeutics NYSEAMERICAN: PTHS reported higher first-quarter revenue as prescriptions for its lead product, ZELSUVMI, continued to grow in the treatment's third full quarter since launch, executives said on the company's 2026 first-quarter earnings call.

Pelthos Therapeutics Inc. (PTHS) Q1 2026 Earnings Call Transcript

Pelthos Therapeutics Inc. (PTHS) Q1 2026 Earnings Call Transcript

Pelthos Therapeutics Inc. (PTHS) Q1 2026 Earnings Call Transcript

Pelthos Therapeutics Inc. (PTHS) Reports Q1 Loss, Beats Revenue Estimates

Pelthos Therapeutics Inc. (PTHS) Reports Q1 Loss, Beats Revenue Estimates

Pelthos Therapeutics Inc. (PTHS) came out with a quarterly loss of $3.09 per share versus the Zacks Consensus Estimate of a loss of $4. This compares to a loss of $3.2 per share a year ago.

Pelthos Therapeutics Announces First Quarter 2026 Financial Results

Pelthos Therapeutics Announces First Quarter 2026 Financial Results

ZELSUVMI ® net product revenue grew 17% quarter over quarter from $9.1 million in the fourth quarter of 2025 to $10.7 million in the first quarter of 2026 7,884 ZELSUVMI units prescribed by 3,228 unique prescribers for the first quarter of 2026, with a 25% quarter over quarter increase in units dispensed Management will host a conference call today, May 14, 2026, at 8:30 a.m. ET DURHAM, N.C.

Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain

Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain

First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease

Pelthos Therapeutics Inc. (PTHS) Q4 2025 Earnings Call Transcript

Pelthos Therapeutics Inc. (PTHS) Q4 2025 Earnings Call Transcript

Pelthos Therapeutics Inc. (PTHS) Q4 2025 Earnings Call Transcript

Видео

No Data

There is no data to display

Пресс-релизы

Pelthos Therapeutics Announces First Quarter 2026 Financial Results

Pelthos Therapeutics Announces First Quarter 2026 Financial Results

ZELSUVMI ® net product revenue grew 17% quarter over quarter from $9.1 million in the fourth quarter of 2025 to $10.7 million in the first quarter of 2026 7,884 ZELSUVMI units prescribed by 3,228 unique prescribers for the first quarter of 2026, with a 25% quarter over quarter increase in units dispensed Management will host a conference call today, May 14, 2026, at 8:30 a.m. ET DURHAM, N.C.

Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain

Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain

First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease

Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

ZELSUVMI ™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December 31, 2025. Total revenue including licensing revenue was $16.8 million for 2025.

Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics

Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics

FARMINGTON, Conn.--(BUSINESS WIRE)--Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”) (the “Company”), an affiliate of Monroe Capital, today announced it has provided a $50 million venture loan facility to Pelthos Therapeutics Inc. (NYSE American: PTHS) (“Pelthos”), with an initial funding of $30 million, and up to $20 million to support future growth. Pelthos is a publicly traded biopharmaceutical company that is licensed to commercialize ZELSUVMI™ (berdazimer) topical gel, an.